StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Nabriva Therapeutics stock opened at $0.00 on Friday. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company has a market capitalization of $6,403.00, a price-to-earnings ratio of 0.00 and a beta of 1.53. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- Investing In Automotive Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Overbought Stocks Explained: Should You Trade Them?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Health Care Stocks Explained: Why You Might Want to Invest
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.